Brief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
02/07/2025 21:20
July 2 (Reuters) - Elevation Oncology Inc ELEV.O: ELEVATION ONCOLOGY INC -LICENSE AGREEMENT WITH CSPC MEGALITH BIOPHARMACEUTICAL TERMINATED AS OF JUNE 26, 2025 - SEC FILING ELEVATION ONCOLOGY INC - TERMINATION AGREEMENT INCLUDES MUTUAL RELEASE OF CLAIMS - SEC FILING Further company coverage: ELEV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing